The best dose of concurrent chemoradiotherapy for esophageal cancer exists
individual difference because of tumor heterogeneity. The treatment will be
more predictable if we can assess the chemoradiotherapy earlier, which will be helpful
in early intervention for optimization of treatment plan, treatment time and improvement
of overall survival. Multi-parametric MRI is gradually used for evaluating tumor treatment, and provides earlier
and more information than conventional MRI. In this study, we used Ktrans value
(derived from DCE-MRI) and ADC value (derived from DWI) to assess treatment
response after the fifth concurrent chemoradiotherapy in esophageal cancer.
This abstract and the presentation materials are available to members only; a login is required.